Loading…
Fujian-based pharmaceutical/biotech company; specific pipeline and products not fully confirmed from available knowledge.
Fujian-based pharmaceutical/biotech company; specific pipeline and products not fully confirmed from available knowledge.
Moat: none
Headquarters: Fujian, China · Employees: 715
Size Fujian Cosunter Pharmaceutical (300436.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.26B, the 1125th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥75.73 on 6 Nov 2026.
Performance Over six months the shares fell 35.4%, against -6.5% for the median peer and -16.4% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue fell 0.4% over the last twelve months (peer median +0.1%); the operating margin is -47.0% (peer median 9.7%).
Valuation It trades at 34.7× enterprise value to sales against a peer median of 3.4× (3rd most expensive of 20).
Capital Return on invested capital runs 28.2 points below its cost of capital (14.1% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥429M | CN¥413M | CN¥438M | CN¥414M | CN¥382M |
| Revenue growth | — | -6% | +6% | +8% | — |
| Gross profit | CN¥298M | CN¥214M | CN¥229M | CN¥199M | CN¥197M |
| EBITDA | n/a | -CN¥35.8M | -CN¥46.2M | -CN¥135M | -CN¥173M |
| Net income | -CN¥210M | -CN¥218M | -CN¥156M | -CN¥349M | -CN¥127M |
| Free cash flow | -CN¥138M | -CN¥94.6M | -CN¥28.6M | -CN¥376M | -CN¥315M |
| Capital expenditure | CN¥81.4M | CN¥59.5M | CN¥67.0M | CN¥201M | CN¥196M |
| Total debt | CN¥485M | CN¥728M | CN¥697M | CN¥696M | CN¥313M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Fujian Cosunter Pharmaceutical 300436.SZ | $2.26B | -35% | 0% | -47% | 34.7× | n/a |
| Gilead Sciences GILD | $207B | +28% | +7% | 38% | 7.2× | -2.9% |
| Sbp 1177.HK | $12.7B | +4% | +15% | 30% | 2.7× | -5.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300436.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.3% | +0.7% | 7th lowest of 21 |
| 6-month return | -35.4% | -6.5% | 3rd lowest of 21 |
| Distance from 52-week high | -49.2% | -25.4% | 3rd lowest of 21 |
| Revenue growth (TTM) | -0.4% | +0.1% | 10th lowest of 20 |
| Operating margin | -47.0% | 9.7% | 4th lowest of 19 |
| EV / Sales | 34.7× | 3.4× | 3rd most expensive of 20 |
| ROIC minus cost of capital | -28.2 pp | +1.6 pp | 3rd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.26B | -35% | 0% | -47% | 34.7× | n/a | n/a |
| NewAmsterdam Pharma NAMS | United States | $2.26B | -51% | -26% | -900% | 62.8× | n/a | n/a |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.29B | -14% | +18% | n/a | 4.4× | 1.6% | +0.3% |
| InnoCare Pharma 9969.HK | Hong Kong | $2.31B | -13% | +146% | 35% | 3.4× | 0.8% | +341.1% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.31B | -7% | +4% | 10% | 1.5× | -2.2% | -5.8% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.32B | +18% | -7% | 15% | 1.8× | -9.1% | -1.5% |
| Perrigo PRGO | United States | $2.20B | +35% | -4% | 5% | 1.3× | 13.1% | +0.8% |
| Biohaven BHVN | United States | $2.19B | +47% | n/a | n/a | n/a | n/a | n/a |
| Haw Par H02.SI | Singapore | $2.18B | -27% | -13% | 30% | 8.9× | 3.7% | +15.7% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.15B | -3% | +9% | 14% | 3.4× | 6.1% | +6.4% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $2.13B | -27% | +5% | -18% | 30.2× | n/a | n/a |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $2.12B | -41% | -18% | 9% | 15.5× | 37.9% | +0.9% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.12B | +17% | -1% | 14% | 2.5× | 2.4% | +15.7% |
| Dermapharm DMP.DE | Germany | $2.11B | -25% | 0% | 22% | 2.4× | -3.8% | +8.0% |
| Zymeworks ZYME | United States | $2.10B | +24% | -70% | -419% | 56.6× | n/a | n/a |
| Harbin Pharmaceutical 600664.SS | China | $2.10B | +55% | +2% | 5% | 0.9× | -2.9% | +8.2% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.48B | -6% | 0% | -73% | 17.5× | n/a | n/a |
| Jinyu Bio-Technology 600201.SS | China | $2.04B | -15% | +22% | 10% | 7.7× | 24.4% | -2.4% |
| Prestige Consumer Healthcare PBH | United States | $2.04B | -18% | -1% | 26% | 3.6× | -0.2% | +2.9% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.02B | +7% | +5% | 22% | 3.2× | -4.8% | +10.6% |
| Qingdao Baheal Medical 301015.SZ | China | $2.02B | +4% | -6% | 8% | 2.2× | 11.9% | +5.0% |